| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Alligator Bioscience AB (publ) (ST: ATORX)
ATORX Technical Analysis
5
| As on 9th Jun 2023 ATORX STOCK Price closed @ 0.50 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.83 & Strong Sell for SHORT-TERM with Stoploss of 2.37 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ATORXSTOCK Price
| Open | 0.54 | Change | Price | % |
| High | 0.54 | 1 Day | -0.02 | -3.85 |
| Low | 0.48 | 1 Week | -0.03 | -5.66 |
| Close | 0.50 | 1 Month | -0.22 | -30.56 |
| Volume | 939446 | 1 Year | -1.81 | -78.35 |
| 52 Week High 2.58 | 52 Week Low 0.46 | ||||
ST Sweden Most Active Stocks
| QUIA | 0.02 | 0.00% |
| QLIFE | 0.04 | 0.00% |
| SBB-B | 5.38 | 3.07% |
| STRLNG | 0.12 | 33.33% |
| LUNE | 21.97 | 6.65% |
| SAS | 0.36 | 5.88% |
| URBIT | 0.02 | 0.00% |
| IDOGEN | 0.15 | -31.82% |
| STAR-B | 0.89 | -1.11% |
| TELIA | 24.60 | 0.41% |
ST Sweden Top Gainers Stocks
ST Sweden Top Losers Stocks
| ATORX Daily Charts |
ATORX Intraday Charts |
Whats New @ Bazaartrend |
ATORX Free Analysis |
|
|
ATORX Important Levels Intraday
| RESISTANCE | 0.62 |
| RESISTANCE | 0.58 |
| RESISTANCE | 0.56 |
| RESISTANCE | 0.53 |
| SUPPORT | 0.47 |
| SUPPORT | 0.44 |
| SUPPORT | 0.42 |
| SUPPORT | 0.38 |
ATORX Forecast May 2024
| 4th UP Forecast | 1.27 |
| 3rd UP Forecast | 1.02 |
| 2nd UP Forecast | 0.87 |
| 1st UP Forecast | 0.72 |
| 1st DOWN Forecast | 0.28 |
| 2nd DOWN Forecast | 0.13 |
| 3rd DOWN Forecast | -0.02 |
| 4th DOWN Forecast | -0.27 |
ATORX Weekly Forecast
| 4th UP Forecast | 1.41 |
| 3rd UP Forecast | 1.12 |
| 2nd UP Forecast | 0.94 |
| 1st UP Forecast | 0.76 |
| 1st DOWN Forecast | 0.24 |
| 2nd DOWN Forecast | 0.06 |
| 3rd DOWN Forecast | -0.12 |
| 4th DOWN Forecast | -0.41 |
ATORX Forecast2024
| 4th UP Forecast | 4.93 |
| 3rd UP Forecast | 3.51 |
| 2nd UP Forecast | 2.63 |
| 1st UP Forecast | 1.75 |
| 1st DOWN Forecast | -0.75 |
| 2nd DOWN Forecast | -1.63 |
| 3rd DOWN Forecast | -2.51 |
| 4th DOWN Forecast | -3.93 |
Alligator Bioscience AB (publ) ( ST Sweden Symbol : ATORX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ATORX Business Profile
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in the United States, Sweden, Asia, and internationally. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial to treat metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden. Address: Medicon Village, Lund, Sweden, 223 81
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service